Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 32 of 32 publications.

DiBenedetti D, Neme D, Pan-Petesch B, Willemze A, Wynn T, Kragh N, Wilson A. Patient experience with efanesoctocog alfa for severe hemophilia A: results from the XTEND-1 phase 3 clinical study exit interviews. Clin Ther. 2024 Oct 15;S0149-291. doi: 10.1016/j.clinthera.2024.09.010

Swertz M, van Enckevort E, Oliveira JL, Fortier I, Bergeron J, Thurin NH, Hyde E, Kellmann A, Pajouheshnia R, Sturkenboom M, Cunnington M, Nybo Andersen A-M, Marcon Y, Goncalves G, Gini R. Towards an interoperable ecosystem of research cohort and real-world data catalogues enabling multi-center studies. Yearb Med Inform. 2022 Aug;31(1):262-72. doi: 10.1055/s-0042-1742522

Meyers J, Hoog M, Mody R, Yu M, Davis K. The health care resource utilization and costs among patients with type 2 diabetes and either cardiovascular disease or cardiovascular risk factors an analysis of a US health insurance database. Clin Ther. 2021 Nov;43(11):1827-42. doi: 10.1016/j.clinthera.2021.09.003

Ervin C, Joish VN, Evans E, DiBenedetti D, Reaney M, Preblick R, Castro R, Danne T, Buse JB, Lapuerta P. Insights into patients' experience with Type 1 diabetes: exit interviews from phase III studies of sotagliflozin. Clin Ther. 2019 Nov;41(11):2219-2230. doi: 10.1016/j.clinthera.2019.09.003

Meyers J, Sinha A, Samant S, Candrilli S. The economic burden of congenital cytomegalovirus disease in the first year of life: a retrospective analysis of health insurance claims data in the United States. Clin Ther. 2019 Jun;41(6):1040-1056. doi: 10.1016/j.clinthera.2019.04.022

Lin HM, Davis KL, Kaye JA, Luptakova K, Nagar SP, Mohty M. Real-world treatment patterns, outcomes, and healthcare resource utilization in relapsed or refractory multiple myeloma: evidence from a medical record review in France. Adv Hematol. 2019 Jan 29;2019(4625787). doi: 10.1155/2019/4625787

Maiese EM, Ainsworth C, Le Moine JG, Ahdesmaki O, Bell J, Hawe E. In reply: Network meta-analyses are not about a single treatment but about sets of regimens. Clin Ther. 2019 Jan;41(1):188-90. doi: 10.1016/j.clinthera.2018.11.011

Maiese EM, Ainsworth C, Le Moine JG, Ahdesmaki O, Bell J, Hawe E. Comparative efficacy of treatments for previously treated multiple myeloma: a systematic literature review and network meta-analysis. Clin Ther. 2018 Mar;40(3):480-94. doi: 10.1016/j.clinthera.2018.01.014

Pontes C, Marsal JR, Elorza JM, Aragon M, Prieto-Alhambra D, Morros R. Analgesic use and risk for acute coronary events in patients with osteoarthritis: a population-based, nested case-control study. Clin Ther. 2018 Feb;40(2):270-83. doi: 10.1016/j.clinthera.2017.12.011

Anthony L, Ervin C, Lapuerta P, Kulke MH, Kunz P, Bergsland E, Horsch D, Metz DC, Pasieka J, Pavlakis N, Pavel M, Caplin M, Oberg K, Ramage J, Evans E, Yang QM, Jackson S, Arnold K, Law L, DiBenedetti DB. Understanding the patient experience with carcinoid syndrome: exit interviews from a randomized, placebo-controlled study of telotristat ethyl. Clin Ther. 2017 Nov 11;39(11):2158-68. doi: 10.1016/j.clinthera.2017.09.013

Earnshaw SR, McDade CL, Chu Y, Fleige LE, Sievenpiper JL. Cost-effectiveness of maintaining daily intake of oat β-glucan for coronary heart disease primary prevention. Clin Ther. 2017 Apr;39(4):804-818.e. doi: 10.1016/j.clinthera.2017.02.012

Donohue JF, Ganapathy V, Bollu V, Stensland MD, Nelson LM. Health status of patients with moderate to severe COPD after treatment with nebulized arformoterol tartrate or placebo for 1 year. Clin Ther. 2017 Jan;39(1):66-74. doi: 10.1016/j.clinthera.2016.11.021

Mladsi D, Ronquest N, Odom D, Miles L, Saag K. Cost-effectiveness of low-dose submicron diclofenac compared with generic diclofenac. Clin Ther. 2016 Nov;38(11):2418-29. doi: 10.1016/j.clinthera.2016.09.013

Bailey RA, Schwab P, Xu Y, Pasquale M, Renda A. Glycemic control outcomes after Canagliflozin initiation: observations in a Medicare and commercial managed care population in clinical practice. Clin Ther. 2016 Sep;38(9):2046-2057. doi: 10.1016/j.clinthera.2016.07.009

Graham CN, Maglinte GA, Schwartzberg LS, Price TJ, Knox HN, Hechmati G, Hjelmgren J, Barber B, Fakih MG. Economic analysis of panitumumab compared with cetuximab in patients with wild-type KRAS metastatic colorectal cancer that progressed after standard chemotherapy. Clin Ther. 2016 Jun;38(6):1376-91. doi: 10.1016/j.clinthera.2016.03.023

Kan H, Nagar S, Patel J, Wallace DJ, Molta C, Chang DJ. Longitudinal treatment patterns and associated outcomes in patients with newly diagnosed systemic lupus erythematosus. Clin Ther. 2016 Mar;38(3):610-24. doi: 10.1016/j.clinthera.2016.01.016

Davis KL, Cote I, Kaye JA, Mendelson E, Gao H, Perez Ronco J. Real-world assessment of clinical outcomes in patients with lower-risk myelofibrosis receiving treatment with ruxolitinib. Adv Hematol. 2015 Oct;2015(2015):848473. doi: 10.1155/2015/848473

Barnes R, Earnshaw S, Herbrecht R, Morrissey O, Slavin M, Bow E, McDade C, Charbonneau C, Weinstein D, Kantecki M, Schlamm H, Maertens J. Economic comparison of an empirical versus diagnostic-driven strategy for treating invasive fungal disease in immunocompromised patients. Clin Ther. 2015 Jun 1;37(6):1317-28. doi: 10.1016/j.clinthera.2015.03.021

Odom DM, Mladsi DM, Saag KG, Sherif BN, Miles L, Ronquest N, Wang J. Relationship between diclofenac dose and risk of gastrointestinal and cardiovascular events: meta-regression based on two systematic literature reviews. Clin Ther. 2014 Jun;36(6):906-17. doi: 10.1016/j.clinthera.2014.04.012.

Hagiwara M, Borker R, Oster G. Economic burden of adverse events in patients with metastatic renal cell carcinoma. Clin Ther. 2013 Dec;35(12):1955-1963. doi: 10.1016/j.clinthera.2013.10.010

Coon CD, McLeod LD. Patient-reported outcomes: current perspectives and future directions. Clin Ther. 2013 Apr 1;35(4):399-401.

Earnshaw SR, McDade C, Chapman AM, Jackson D, Schwamm L. Economic impact of using additional diagnostic tests to better select patients with stroke for intravenous thrombolysis in the United Kingdom. Clin Ther. 2012 Jul 1;34(7):1544-58.

Becker N, Fortuny J, Alvaro T, Nieters A, Maynadie M, Foretova L, Staines A, Brennan P, Boffetta P, Cocco PL, de Sanjose S. Medical history and risk of lymphoma: results of a European case-control study (EPILYMPH). J Cancer Res Clin Oncol. 2009 Aug;135(8):1099-107. doi: 10.1007/s00432-009-0551

Wolowacz SE, Roskell NS, Maciver F, Beard SM, Robinson PA, Plumb JM, Dolan G, Brenkel IJ. Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism after total knee and hip replacement surgery. Clin Ther. 2009 Jan 1;31(1):194-212.

Rothman KJ. BMI-related errors in the measurement of obesity. Int J Obes. 2008 Aug 1;32 Suppl 3:S56-9.

Meltzer EO, Stahlman JE, Leflein J, Meltzer S, Lim J, Dalal AA, Prillaman BA, Philpot EE. Preferences of adult patients with allergic rhinitis for the sensory attributes of fluticasone furoate versus fluticasone propionate nasal sprays: a randomized, multicenter, double-blind, single-dose, crossover study. Clin Ther. 2008 Feb;30(2):271-9. doi: 10.1016/j.clinthera.2008.02.005

Earnshaw SR, Moride Y, Rochon S. Cost-effectiveness of pegaptanib compared to photodynamic therapy with verteporfin and to standard care in the treatment of subfoveal wet age-related macular degeneration in Canada. Clin Ther. 2007 Sep 1;29(9):2096-106.

Sanchez-Matienzo D, Arana A, Castellsague J, Perez-Gutthann S. Hepatic disorders in patients treated with COX-2 selective inhibitors or nonselective NSAIDs: a case/noncase analysis of spontaneous reports. Clin Ther. 2006 Aug 1;28(8):1123-32.

Sanchez-Matienzo D, Arana A, Castellsague J, Perez-Gutthann S. Hepatic disorders in users of NSAIDs, including COX-2 selective inhibitors. A case/non-case analysis of spontaneous reports. Clin Ther. 2006;28(8):1123-32.

Sapienza S, Sacco P, Floyd K, DiCesare J, Doan Q. Results of a pilot pharmacotherapy quality improvement program using fixed-dose, combination amlodipine/benazepril antihypertensive therapy in a long-term care setting. Clin Ther. 2003 Jun;25(6):1872-87.

Caro JJ, Klittich WS, Raggio G, Kavanagh PL, O'Brien JA, Shomphe LA, Flegel KM, Copley-Merriman C, Sigler C. Economic assessment of troglitazone as an adjunct to sulfonylurea therapy in the treatment of type 2 diabetes. Clin Ther. 2000 Jan;22(1):116-27.

Sorensen HT, Sabroe S, Gillman M, Rothman KJ, Madsen KM, Fischer P. Continued increase in prevalence of obesity in young Danish men. Int J Obes. 1997 Aug;21(8):712-4.